Barclays PLC Silence Therapeutics PLC Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 6,126 shares of SLN stock, worth $27,567. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,126
Previous 3,333
83.8%
Holding current value
$27,567
Previous $61,000
31.15%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SLN
# of Institutions
66Shares Held
24.6MCall Options Held
500Put Options Held
5K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$13.7 Million3.41% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$12.7 Million0.86% of portfolio
-
Redmile Group, LLC San Francisco, CA2.4MShares$10.8 Million1.29% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.86MShares$8.35 Million1.01% of portfolio
-
Morgan Stanley New York, NY1.66MShares$7.48 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $161M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...